{"classes":[{"categories":[{"measurements":[{"comment":"Insufficient number of participants with events","groupId":"OG000","lowerLimit":"54.9","upperLimit":"NA","value":"NA"},{"comment":"Insufficient number of participants with events","groupId":"OG001","lowerLimit":"0.3","upperLimit":"NA","value":"11.2"},{"comment":"Insufficient number of participants with events","groupId":"OG002","lowerLimit":"52.7","upperLimit":"NA","value":"NA"},{"comment":"Insufficient number of participants with events","groupId":"OG003","lowerLimit":"52.7","upperLimit":"NA","value":"NA"},{"comment":"Insufficient number of participants with events","groupId":"OG004","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"81"},{"groupId":"OG003","value":"50"},{"groupId":"OG004","value":"31"}],"units":"Participants"}],"description":"Duration of MCyR will be computed from the first day criteria are met for MCyR until the date progressive disease (PD) is reported (or treatment is discontinued for PD) or death. Participants who neither discontinue due to PD nor die will be censored on the date of their last hematologic or cytogenetic assessment, whichever comes last. (Based on \\>=20 Metaphases)","dispersionType":"95% Confidence Interval","groups":[{"description":"Children and adolescents with CP-CML who were resistant or intolerant to imatinib received dasatinib tablets at 60 mg/m2 QD on a continuous oral regimen.","id":"OG000","title":"Cohort 1"},{"description":"Children and adolescents with Ph+ ALL, AP-CML or BP-CML who were resistant or intolerant to, or relapsed after imatinib therapy received dasatinib tablets at a dose schedule of 80 mg/m2 QD on a continuous oral regimen.","id":"OG001","title":"Cohort 2"},{"description":"Children and adolescents with CP-CML who were treatment-naive received dasatinib tablets at 60 mg/m2 QD or powder for oral suspension (PFOS) at 72 mg/m2 QD on a continuous oral regimen.","id":"OG002","title":"Cohort 3"},{"description":"Children and adolescents with CP-CML who were treatment-naive received dasatinib tablets at 60 mg/m2 QD on a continuous oral regimen.","id":"OG003","title":"Cohort 3a"},{"description":"Children and adolescents with CP-CML who were treatment-naive received dasatinib powder for oral suspension (PFOS) at 72 mg/m2 QD on a continuous oral regimen.","id":"OG004","title":"Cohort 3b"}],"paramType":"MEDIAN","populationDescription":"All treated participants with MCyR","reportingStatus":"POSTED","timeFrame":"From first day criteria are met for MCyR until the date PD is reported or death (assessed up to September 2016, approximately 90 months)","title":"Duration of Major Cytogenetic Response (MCyR)","type":"SECONDARY","unitOfMeasure":"months"}